vs
Side-by-side financial comparison of Adagene Inc. (ADAG) and ASTRAZENECA PLC (AZN). Click either name above to swap in a different company.
Adagene Inc. is a global clinical-stage biotechnology company specializing in the research, development, and commercialization of innovative antibody-based cancer immunotherapies. Leveraging its proprietary next-generation antibody technology platforms, it develops targeted oncology treatments for patients across global markets, with core R&D bases in China and clinical programs covering North America, Asia, and Europe.
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $14.5B | ||
| Q2 24 | — | $12.9B | ||
| Q2 23 | — | $11.4B | ||
| Q2 22 | — | $10.8B |
| Q2 25 | — | $2.4B | ||
| Q2 24 | — | $1.9B | ||
| Q2 23 | — | $1.8B | ||
| Q2 22 | — | $360.0M |
| Q2 25 | — | 82.9% | ||
| Q2 24 | — | 83.1% | ||
| Q2 23 | — | 82.8% | ||
| Q2 22 | — | 72.2% |
| Q2 25 | — | 24.3% | ||
| Q2 24 | — | 21.2% | ||
| Q2 23 | — | 21.5% | ||
| Q2 22 | — | 5.0% |
| Q2 25 | — | 16.9% | ||
| Q2 24 | — | 14.9% | ||
| Q2 23 | — | 15.9% | ||
| Q2 22 | — | 3.3% |
| Q2 25 | — | $1.57 | ||
| Q2 24 | — | $1.24 | ||
| Q2 23 | — | $1.17 | ||
| Q2 22 | — | $0.23 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
